Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 481 to 490 of 490 entries
Sorted by: Best Match Show Resources per page
Laparoscopic surgery for recurrent Crohn's disease.

Gastroenterology research and practice

Spinelli A, Sacchi M, Bazzi P, Leone N, Danese S, Montorsi M.
PMID: 22253619
Gastroenterol Res Pract. 2012;2012:381017. doi: 10.1155/2012/381017. Epub 2012 Jan 02.

In spite of the recent improvements in drug therapy, surgery still represents the most frequent treatment for Crohn's disease (CD) complications. Laparoscopy has been widely applied over the last twenty years in colorectal surgery and was associated with lower...

Cite
Spinelli A, Sacchi M, Bazzi P, et al. Laparoscopic surgery for recurrent Crohn's disease. Gastroenterol Res Pract. 2012;2012:381017doi: 10.1155/2012/381017.
Spinelli, A., Sacchi, M., Bazzi, P., Leone, N., Danese, S., & Montorsi, M. (2012). Laparoscopic surgery for recurrent Crohn's disease. Gastroenterology research and practice, 2012381017. https://doi.org/10.1155/2012/381017
Spinelli, Antonino, et al. "Laparoscopic surgery for recurrent Crohn's disease." Gastroenterology research and practice vol. 2012 (2012): 381017. doi: https://doi.org/10.1155/2012/381017
Spinelli A, Sacchi M, Bazzi P, Leone N, Danese S, Montorsi M. Laparoscopic surgery for recurrent Crohn's disease. Gastroenterol Res Pract. 2012;2012:381017. doi: 10.1155/2012/381017. Epub 2012 Jan 02. PMID: 22253619; PMCID: PMC3255167.
Copy Download .nbib Format: NLM
Is Upregulation of Sarcolipin Beneficial or Detrimental to Muscle Function?.

Frontiers in physiology

Bal NC, Gupta SC, Pant M, Sopariwala DH, Gonzalez-Escobedo G, Turner J, Gunn JS, Pierson CR, Harper SQ, Rafael-Fortney JA, Periasamy M.
PMID: 33732165
Front Physiol. 2021 Mar 01;12:633058. doi: 10.3389/fphys.2021.633058. eCollection 2021.

Sarcolipin (SLN) is a regulator of sarco/endo plasmic reticulum Ca

Cite
Bal NC, Gupta SC, Pant M, et al. Is Upregulation of Sarcolipin Beneficial or Detrimental to Muscle Function?. Front Physiol. 2021;12:633058doi: 10.3389/fphys.2021.633058.
Bal, N. C., Gupta, S. C., Pant, M., Sopariwala, D. H., Gonzalez-Escobedo, G., Turner, J., Gunn, J. S., Pierson, C. R., Harper, S. Q., Rafael-Fortney, J. A., & Periasamy, M. (2021). Is Upregulation of Sarcolipin Beneficial or Detrimental to Muscle Function?. Frontiers in physiology, 12633058. https://doi.org/10.3389/fphys.2021.633058
Bal, Naresh C, et al. "Is Upregulation of Sarcolipin Beneficial or Detrimental to Muscle Function?." Frontiers in physiology vol. 12 (2021): 633058. doi: https://doi.org/10.3389/fphys.2021.633058
Bal NC, Gupta SC, Pant M, Sopariwala DH, Gonzalez-Escobedo G, Turner J, Gunn JS, Pierson CR, Harper SQ, Rafael-Fortney JA, Periasamy M. Is Upregulation of Sarcolipin Beneficial or Detrimental to Muscle Function?. Front Physiol. 2021 Mar 01;12:633058. doi: 10.3389/fphys.2021.633058. eCollection 2021. PMID: 33732165; PMCID: PMC7956958.
Copy Download .nbib Format: NLM
Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?.

Life (Basel, Switzerland)

Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S.
PMID: 34357022
Life (Basel). 2021 Jul 04;11(7). doi: 10.3390/life11070649.

Bowel ultrasound (BUS) is a non-invasive and accurate technique for assessing activity, extension of disease, and complications in inflammatory bowel diseases. The main advantages of BUS are its safety, reproducibility, and low costs. Ancillary technologies of BUS (i.e., color...

Cite
Furfaro F, Dal Buono A, Allocca M, et al. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. Life (Basel). 2021;11(7)doi: 10.3390/life11070649.
Furfaro, F., Dal Buono, A., Allocca, M., D'Amico, F., Zilli, A., Gabbiadini, R., & Danese, S. (2021). Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. Life (Basel, Switzerland), 11(7), . https://doi.org/10.3390/life11070649
Furfaro, Federica, et al. "Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?." Life (Basel, Switzerland) vol. 11,7 (2021). doi: https://doi.org/10.3390/life11070649
Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?. Life (Basel). 2021 Jul 04;11(7). doi: 10.3390/life11070649. PMID: 34357022; PMCID: PMC8308056.
Copy Download .nbib Format: NLM
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Nature reviews. Gastroenterology & hepatology

Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L.
PMID: 34453143
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857-873. doi: 10.1038/s41575-021-00492-8. Epub 2021 Aug 27.

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations...

Cite
Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857-873doi: 10.1038/s41575-021-00492-8.
Olivera, P. A., Zuily, S., Kotze, P. G., Regnault, V., Al Awadhi, S., Bossuyt, P., Gearry, R. B., Ghosh, S., Kobayashi, T., Lacolley, P., Louis, E., Magro, F., Ng, S. C., Papa, A., Raine, T., Teixeira, F. V., Rubin, D. T., Danese, S., & Peyrin-Biroulet, L. (2021). International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology, 18(12), 857-873. https://doi.org/10.1038/s41575-021-00492-8
Olivera, Pablo A, et al. "International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease." Nature reviews. Gastroenterology & hepatology vol. 18,12 (2021): 857-873. doi: https://doi.org/10.1038/s41575-021-00492-8
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857-873. doi: 10.1038/s41575-021-00492-8. Epub 2021 Aug 27. PMID: 34453143; PMCID: PMC8395387.
Copy Download .nbib Format: NLM
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.

Journal of Crohn's & colitis

Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV, Panes J, Danese S.
PMID: 34107013
J Crohns Colitis. 2021 Dec 18;15(12):2022-2030. doi: 10.1093/ecco-jcc/jjab099.

BACKGROUND AND AIMS: Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in clinical trials. We evaluated how these symptoms may improve with upadacitinib treatment and correlate with clinical and health-related quality...

Cite
Ghosh S, Sanchez Gonzalez Y, Zhou W, et al. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis. 2021;15(12):2022-2030doi: 10.1093/ecco-jcc/jjab099.
Ghosh, S., Sanchez Gonzalez, Y., Zhou, W., Clark, R., Xie, W., Louis, E., Loftus, E. V., Panes, J., & Danese, S. (2021). Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. Journal of Crohn's & colitis, 15(12), 2022-2030. https://doi.org/10.1093/ecco-jcc/jjab099
Ghosh, Subrata, et al. "Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis." Journal of Crohn's & colitis vol. 15,12 (2021): 2022-2030. doi: https://doi.org/10.1093/ecco-jcc/jjab099
Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV, Panes J, Danese S. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis. 2021 Dec 18;15(12):2022-2030. doi: 10.1093/ecco-jcc/jjab099. PMID: 34107013; PMCID: PMC8684481.
Copy Download .nbib Format: NLM
Research, Practice, and Policy Implications of Adverse Childhood Events-Reply.

JAMA pediatrics

Baldwin JR, Danese A.
PMID: 33970203
JAMA Pediatr. 2021 Aug 01;175(8):867-868. doi: 10.1001/jamapediatrics.2021.0813.

No abstract available.

Cite
Baldwin JR, Danese A. Research, Practice, and Policy Implications of Adverse Childhood Events-Reply. JAMA Pediatr. 2021;175(8):867-868doi: 10.1001/jamapediatrics.2021.0813.
Baldwin, J. R., & Danese, A. (2021). Research, Practice, and Policy Implications of Adverse Childhood Events-Reply. JAMA pediatrics, 175(8), 867-868. https://doi.org/10.1001/jamapediatrics.2021.0813
Baldwin, Jessie R, and Danese, Andrea. "Research, Practice, and Policy Implications of Adverse Childhood Events-Reply." JAMA pediatrics vol. 175,8 (2021): 867-868. doi: https://doi.org/10.1001/jamapediatrics.2021.0813
Baldwin JR, Danese A. Research, Practice, and Policy Implications of Adverse Childhood Events-Reply. JAMA Pediatr. 2021 Aug 01;175(8):867-868. doi: 10.1001/jamapediatrics.2021.0813. PMID: 33970203.
Copy Download .nbib Format: NLM
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Therapeutic advances in gastroenterology

Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S.
PMID: 34917173
Therap Adv Gastroenterol. 2021 Dec 09;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021.

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments...

Cite
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021;14:17562848211059954doi: 10.1177/17562848211059954.
Peyrin-Biroulet, L., Sandborn, W. J., Panaccione, R., Domènech, E., Pouillon, L., Siegmund, B., Danese, S., & Ghosh, S. (2021). Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therapeutic advances in gastroenterology, 1417562848211059954. https://doi.org/10.1177/17562848211059954
Peyrin-Biroulet, Laurent, et al. "Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues." Therapeutic advances in gastroenterology vol. 14 (2021): 17562848211059954. doi: https://doi.org/10.1177/17562848211059954
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021 Dec 09;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021. PMID: 34917173; PMCID: PMC8669878.
Copy Download .nbib Format: NLM
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.

Therapeutic advances in gastroenterology

Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S.
PMID: 34917173
Therap Adv Gastroenterol. 2021 Dec 09;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021.

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments...

Cite
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021;14:17562848211059954doi: 10.1177/17562848211059954.
Peyrin-Biroulet, L., Sandborn, W. J., Panaccione, R., Domènech, E., Pouillon, L., Siegmund, B., Danese, S., & Ghosh, S. (2021). Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therapeutic advances in gastroenterology, 1417562848211059954. https://doi.org/10.1177/17562848211059954
Peyrin-Biroulet, Laurent, et al. "Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues." Therapeutic advances in gastroenterology vol. 14 (2021): 17562848211059954. doi: https://doi.org/10.1177/17562848211059954
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021 Dec 09;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021. PMID: 34917173; PMCID: PMC8669878.
Copy Download .nbib Format: NLM
Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D.
PMID: 34896644
Clin Gastroenterol Hepatol. 2021 Dec 09; doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 09.

BACKGROUND AND AIMS: Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally...

Cite
F M, D M, M P, et al. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.004.
F, M., D, M., M, P., B, A., P, L., I, R., Ht, S., P, M., I, M., A, V., J, C., J, M., J, R., C, E., P, S., F, P., L, C., M, S., S, D., C, A., J, A., S, D., L, P. B., Cc, D. (2021). Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.004
F, Magro, et al. "Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.004
F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol. 2021 Dec 09; doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 09. PMID: 34896644.
Copy Download .nbib Format: NLM
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.

Journal of Crohn's & colitis

Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ.
PMID: 34402887
J Crohns Colitis. 2021 Aug 17; doi: 10.1093/ecco-jcc/jjab133. Epub 2021 Aug 17.

BACKGROUND AND AIMS: Report results from VISIBLE 2, a randomised, double-blind, placebo-controlled phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD].METHODS: Following open-label vedolizumab 300...

Cite
Vermeire S, D'Haens G, Baert F, et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2021;doi: 10.1093/ecco-jcc/jjab133.
Vermeire, S., D'Haens, G., Baert, F., Danese, S., Kobayashi, T., Loftus, E. V., Bhatia, S., Agboton, C., Rosario, M., Chen, C., Zhang, W., Kisfalvi, K., & Sandborn, W. J. (2021). Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjab133
Vermeire, Séverine, et al. "Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial." Journal of Crohn's & colitis vol. (2021). doi: https://doi.org/10.1093/ecco-jcc/jjab133
Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2021 Aug 17; doi: 10.1093/ecco-jcc/jjab133. Epub 2021 Aug 17. PMID: 34402887.
Copy Download .nbib Format: NLM
Showing 481 to 490 of 490 entries